These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25708498)

  • 1. Therapy. Targeted delivery of packaged siRNA promotes osteogenesis.
    Duarte JH
    Nat Rev Rheumatol; 2015 Apr; 11(4):196. PubMed ID: 25708498
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy. Aptamer-lipid nanoparticle conjugates for RNAi in bone.
    Sargent J
    Nat Rev Endocrinol; 2015 Apr; 11(4):194. PubMed ID: 25707781
    [No Abstract]   [Full Text] [Related]  

  • 3. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.
    Liang C; Guo B; Wu H; Shao N; Li D; Liu J; Dang L; Wang C; Li H; Li S; Lau WK; Cao Y; Yang Z; Lu C; He X; Au DW; Pan X; Zhang BT; Lu C; Zhang H; Yue K; Qian A; Shang P; Xu J; Xiao L; Bian Z; Tan W; Liang Z; He F; Zhang L; Lu A; Zhang G
    Nat Med; 2015 Mar; 21(3):288-94. PubMed ID: 25665179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
    Wang XL; Wang QQ; Song HF
    Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.
    Sakib Hossain DM; Duttagupta P; Kortylewski M
    Ther Deliv; 2015 Jan; 6(1):1-4. PubMed ID: 25565435
    [No Abstract]   [Full Text] [Related]  

  • 6. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular delivery of RNA-based therapeutics using aptamers.
    Thiel KW; Giangrande PH
    Ther Deliv; 2010 Dec; 1(6):849-61. PubMed ID: 21643487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
    Fattal E; Bochot A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA.
    Wilner SE; Levy M
    Methods Mol Biol; 2016; 1380():211-24. PubMed ID: 26552829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing prostate cancer.
    Toudjarska I; de Fougerolles A
    Nat Biotechnol; 2009 Sep; 27(9):821-3. PubMed ID: 19741638
    [No Abstract]   [Full Text] [Related]  

  • 13. All in the RNA family.
    Davidson BL
    Nat Biotechnol; 2006 Aug; 24(8):951-2. PubMed ID: 16900139
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
    Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
    Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
    de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
    Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery.
    Sun Y; Ye X; Cai M; Liu X; Xiao J; Zhang C; Wang Y; Yang L; Liu J; Li S; Kang C; Zhang B; Zhang Q; Wang Z; Hong A; Wang X
    ACS Nano; 2016 Jun; 10(6):5759-68. PubMed ID: 27176123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles.
    Askarian S; Abnous K; Taghavi S; Oskuee RK; Ramezani M
    Colloids Surf B Biointerfaces; 2015 Dec; 136():355-64. PubMed ID: 26433348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight.
    Ragelle H; Colombo S; Pourcelle V; Vanvarenberg K; Vandermeulen G; Bouzin C; Marchand-Brynaert J; Feron O; Foged C; Préat V
    J Control Release; 2015 Aug; 211():1-9. PubMed ID: 25989603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation.
    Guo B; Zhang B; Zheng L; Tang T; Liu J; Wu H; Yang Z; Peng S; He X; Zhang H; Yue KK; He F; Zhang L; Qin L; Bian Z; Tan W; Liang Z; Lu A; Zhang G
    Bone; 2014 Feb; 59():76-88. PubMed ID: 24246247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
    Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
    J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.